- Home
- FBK vs SUPN Comparison
FBK vs SUPN Comparison
Compare FBK & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBK
- SUPN
- Stock Information
- Founded
- FBK 1906
- SUPN 2005
- Country
- FBK United States
- SUPN United States
- Employees
- FBK N/A
- SUPN N/A
- Industry
- FBK Major Banks
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- FBK Finance
- SUPN Health Care
- Exchange
- FBK Nasdaq
- SUPN Nasdaq
- Market Cap
- FBK 2.1B
- SUPN 1.9B
- IPO Year
- FBK 2016
- SUPN 2012
- Fundamental
- Price
- FBK $45.67
- SUPN $31.52
- Analyst Decision
- FBK Hold
- SUPN Hold
- Analyst Count
- FBK 5
- SUPN 2
- Target Price
- FBK $54.00
- SUPN $36.00
- AVG Volume (30 Days)
- FBK 188.3K
- SUPN 682.9K
- Earning Date
- FBK 07-14-2025
- SUPN 08-05-2025
- Dividend Yield
- FBK 1.67%
- SUPN N/A
- EPS Growth
- FBK 14.69
- SUPN N/A
- EPS
- FBK 2.73
- SUPN 1.11
- Revenue
- FBK $465,280,000.00
- SUPN $667,997,000.00
- Revenue This Year
- FBK $35.47
- SUPN N/A
- Revenue Next Year
- FBK $20.14
- SUPN $12.02
- P/E Ratio
- FBK $16.63
- SUPN $28.62
- Revenue Growth
- FBK 2.18
- SUPN 11.82
- 52 Week Low
- FBK $38.00
- SUPN $25.55
- 52 Week High
- FBK $58.88
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- FBK 56.49
- SUPN 43.52
- Support Level
- FBK $44.26
- SUPN $30.93
- Resistance Level
- FBK $45.46
- SUPN $31.76
- Average True Range (ATR)
- FBK 0.81
- SUPN 0.96
- MACD
- FBK 0.17
- SUPN -0.16
- Stochastic Oscillator
- FBK 76.03
- SUPN 24.04
About FBK FB Financial Corporation
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.